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Abstract 
Background 
Acquired loss of the largest von Willebrand factor multimers is a common hemostatic 
disturbance in patients with aortic valve stenosis (AS), resulting in impaired platelet 
adhesion and increased bleeding risk. AS is also associated with atherosclerosis and 
myocardial infarction (MI). Our aim was to study the clinical outcomes associated 
with AS in MI patients treated with dual antiplatelet therapy (DAPT) in a nationwide 
hospital-based register study. 
Methods 
Based on nationwide hospital discharge registers from Sweden (2005-2010) and 
Denmark (2005-2015), we calculated 1-year incidence rates and hazard ratios of 
bleeding, recurrent MI, and all-cause mortality in MI patients with and without AS 
treated with DAPT. Results from both countries were also combined in a meta-
analysis. 
Results 
We included 50,460 MI patients from Sweden and 50,307 MI patients from Denmark, 
of which 3% had AS. The bleeding rates (per 100 person-years) in Sweden and 
Denmark were 3.2 and 3.3 among patients without AS vs. 9.2 and 8.3 among patients 
with AS. All-cause mortality rates were 7.1 vs. 28.7 in Sweden and 5.8 vs. 30.7 in 
Denmark among patients without and with AS, respectively. Patients with AS had an 
increased risk of bleeding, recurrent MI and all-cause mortality. Combined results 
from both countries were similar for bleeding (hazard ratio 1.59 [0.98-2.59), recurrent 
MI (1.78 [1.25-2.54]), and all-cause mortality (1.76 [1.26-2.47]). 
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Conclusion 
AS was associated with an increased risk of bleeding, recurrent MI and mortality after 
MI when treated with DAPT. Individualized selection of antiplatelet therapy may be 
warranted in this high-risk population. 
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Introduction 
Cardiovascular mortality is a leading cause of death worldwide with an estimated 17.3 
million deaths annually (1). Much of the cardiovascular disease burden is due to 
myocardial infarction (MI) (2). Recognition and treatment of risk factors associated 
with the atherosclerotic process, together with early revascularization therapy and 
antiplatelet therapy with dual antiplatelet therapy (DAPT) have resulted in greatly 
improved outcomes for patients presenting with acute MI (3-4). Although DAPT 
treatment is associated with improved outcomes (4-6), the antithrombotic effect is 
offset by increased bleeding risk (8). 
Aortic valvular stenosis (AS) is one of the most common valvular disorders in 
western countries (8-9). AS is mainly a disease of the elderly, with a steeply 
increasing prevalence with age (8-9). Similar to coronary artery disease, AS is 
associated with calcific degeneration of the aortic valve leaflets with features of lipid 
accumulation and inflammation (10-11).
 
The overlap of risk factors between AS and 
MI is considerable (12). AS therefore also frequently occurs concomitantly with 
coronary artery disease and MI, but the prognostic implications of having both 
conditions remain incompletely understood. One particular concern is the bleeding 
risk associated with AS. A clustering of AS, intestinal angiodysplasia, and bleeding 
was described by Heyde in the 1950s and has subsequently been referred to as 
Heyde’s syndrome (13). Heyde’s observation has been confirmed in several case 
series, with higher rates of gastrointestinal bleeding in patients with AS compared to 
controls (14-15). The mechanism has been attributed to, at least in part, an acquired 
loss of the largest multimers of von Willebrand factor (vWF), a large glycoprotein 
secreted from the endothelium which is central for platelet adhesion (16-18).  
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AS have also been associated with a prothrombotic state, likely influenced by flow 
condition and concurrent atherosclerotic vascular disease (19). An increase in factor 
XI and activated tissue factor with an elevation in markers of thrombin generation in 
severe AS have previously been reported with possible implications for the risk of 
recurrent MI (20-21). The outcomes associated with AS after acute MI in the era of 
widespread DAPT have not previously been investigated and the risk-benefit profile 
of DAPT might be different in the presence of vWF abnormalities. We hypothesized 
that patients with AS would have a higher risk for bleeding events and recurrent MI 
following MI. The current study aimed to examine the relationship of AS with 
bleeding, recurrent MI, and all-cause mortality in MI patients treated with DAPT in a 
large population-based study using hospital-discharge registers in Sweden and 
Denmark. 
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Methods 
All patients in Sweden and Denmark with a hospital discharge diagnosis of MI and a 
DAPT prescription were included in the study, using nationwide registries for each 
country. Inclusion was from 2005 until 2010 in Sweden and 2005 until 2015 in 
Denmark. Patients were followed for up to 1 year, as DAPT is recommended 1 year 
after MI by contemporary guidelines (4). Follow-up ended on December 31, 2010 in 
Sweden and on December 31, 2015 in Denmark. Observational time started 30 days 
after initial MI to allow subjects time to claim DAPT prescriptions and to possibly 
undergo delayed revascularization therapy. Prevalent AS was defined as a diagnosis 
any time up to 30 days after MI, when follow-up started. 
The Swedish and Danish National Patient Registries (NPR) were used to identify 
patients with a first MI, concurrent AS, bleeding requiring hospitalization and 
recurrent MI. Data on mortality and cause of death were obtained from the national 
Cause of Death Registry (CDR), which is nationwide in both Sweden and Denmark 
(22). The NPR includes information on hospital discharge diagnoses of all patients 
cared for in a hospital setting (23-24). In the study period the NPR also included 
diagnoses from specialized outpatient clinics. Both Sweden and Denmark have tax-
financed healthcare systems with fiscal compensation to the departments based on 
mandatory reporting of discharge diagnoses. A unique and anonymous serial number 
based on the personal identification number that all Swedish and Danish citizens 
receive at either birth or immigration was used to link the NPR and CDR (25). 
Diagnosis codes were based on WHO’s International Classification of Disease (ICD) 
version 10; found in online Supplementary table 1.  
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Patients were considered under treatment with various medications if they had 
claimed a prescription within 90 days of the index event or up to 30 days after the 
event, in accordance with previous studies (26). Information regarding 
pharmacotherapy was based on the Danish Registry of Medicinal Product Statistics 
and the Swedish Pharmaceuticals Registry. Pharmacotherapy is also subsidized by the 
tax-financed healthcare system and is considered nationwide and accurate. 
Cardiovascular diagnoses in these registries have previously been validated and have 
a high positive predictive value (23,27-28). Most diagnoses of aortic valvular stenosis 
captured in these registries are based on echocardiographic examination and generally 
represent moderate to severe valvular disease (27). Comorbidities were identified 
from discharge diagnoses in the NPR at any time prior to the index event. 
In both Sweden and Denmark, MI diagnoses are defined according to European 
guidelines and international consensus. Both non-ST-elevation and ST-elevation 
infarction were included in the study. DAPT in combination with coronary 
revascularization, statins, and anti-ischemic drugs such as beta blockers, nitrates and 
angiotensin receptor blockers are the recommended treatment for patients presenting 
with a myocardial infarction (4). During the study period the most common 
combination for DAPT was acetylsalicylic acid and clopidogrel, but other adenosine 
diphosphate receptor inhibitors (e.g. ticagrelor or prasugrel) were also included in the 
Danish analyses (ending in 2015). The addition of oral anticoagulant treatment to 
DAPT in patients with and without AS was explored separately.  
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Diagnostic definitions 
The main outcomes of the study were bleeding, recurrent MI and all-cause mortality. 
Bleeding was defined as one of the following ICD-10 codes (non-fatal and fatal): I60, 
I61, I62, D50, D60, R04, R31, S064-S066, J942, K250, K252, K254, K260, K262, 
K264, K270, K272, K280, K282, K920, and K922. AS was defined as diagnosis code 
I35. MI was defined as diagnosis code I21. Recurrent MI was defined as a new 
diagnosis of MI by diagnosis code I21 or I22 later than 30 days after the primary 
event including both non-fatal and fatal MIs. 
Statistical analysis 
Data for Sweden and Denmark were analyzed separately, as data access restrictions 
did not allow individual-level data to be exported from the official authorities’ data 
servers. MI patients with DAPT were grouped according to presence or absence of 
AS at baseline and according to concomitant use of warfarin treatment. Treatment 
was analyzed by the intention to treat principle, i.e., any breaks in treatment were not 
considered. Kaplan-Meier curves were constructed to visualize unadjusted mortality 
rates after MI for patients with and without AS in each country. Unadjusted incidence 
rates (per 100 person-years) of bleeding, recurrent MI and mortality were also 
calculated for the separate exposure groups. Cox proportional hazards regression 
analysis was used to calculate hazard ratios, adjusted for potential confounders 
including age, sex, calendar year, percutaneous interventions and CABG performed 
within 30 days after index event, treatment with certain drugs (NSAIDs, proton pump 
inhibitors, beta blockers, statins, calcium blockers, thiazides, loop diuretics, 
spironolactone, and/or insulin), previous diagnosis of ischemic heart disease, 
cerebrovascular disease, peripheral arterial disease, liver disease, chronic kidney 
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disease, peptic ulcer disease, chronic obstructive pulmonary disease, rheumatic 
disease, atrial fibrillation, cancer, bleeding, and congestive heart failure. Patients 
without AS and without the use of oral anticoagulants served as the reference group in 
all analyses. Hazard ratios were also analyzed in random-effects meta-analysis using 
the R package “metafor” (29).  
An independent ethics committee approved the study in Sweden. In Denmark, no 
such approval is necessary for unidentifiable data, but the study was approved by the 
Danish data protection agency (reference number 2007-58-0015; internal reference 
GEH-2014-013 I-suite no. 02731). A two-sided p-value <0.05 was considered 
statistically significant for all analyses. Statistical analyses were performed using SAS 
versions 9.2 and 9.4 (SAS Institute, Cary, NC) and R version 3.3.2. 
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
 
 11 
Results 
A total of 50,460 MI patients (mean age 70±12 years, 36% women) from Sweden and 
50,307 MI patients (mean age 66±13 years, 33% women) from Denmark were 
included in the current study (Table 1). Concurrent AS was present in 3% in both 
countries, comprising 1287 patients in Sweden and 1525 patients in Denmark. In 
Sweden 12% and 16% had concurrent atrial fibrillation (in individuals without and 
with AS, respectively). In the Danish population 8% and 22% were diagnosed with 
atrial fibrillation. A large proportion of individuals were treated with statins and beta-
blockers after MI in both countries. RAAS-inhibitors were also used frequently. 
Revascularization therapy within 30 days was performed in 60% of the Swedish 
population and 75% in the Danish population without AS. For patients with AS 
revascularization therapy was less common; only 28% in Sweden and 40% in 
Denmark were treated with either percutaneous coronary intervention (PCI) or 
coronary artery bypass grafting (CABG) within 30 days after MI. During follow-up 
106 (8%) with AS were censored due to valve replacement surgery (mean time after 
follow-up to surgery 78, SD: 77 days) in Sweden and 197 patients (13%) in Denmark 
(mean time to surgery 78, SD:85 days).   
 
Bleeding rates 
The bleeding rates (per 100 person-years) in Sweden and Denmark were 3.2 and 3.3 
among patients without AS vs. 9.2 and 8.3 among patients with AS (Table 2). The 
increased risk for bleeding among patients with AS persisted after adjustments in 
Sweden (hazard ratio [HR]: 2.04, 95% confidence interval [CI]=1.61-2.59, Table 3) 
but not in Denmark (HR: 1.24, 95% CI=0.98-1.57). In the combined analysis with 
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data from both countries there was a trend towards increased bleeding risk but it was 
not statistically significant (Figure 1, HR: 1.59, 95% CI=0.98-2.59). In a sensitivity 
analysis, patients with AS who had revascularization performed the results remained 
almost identical with an increased risk of bleeding events in Sweden but not in 
Denmark (Supplementary Table 1) 
 
Recurrent MI rates  
For patients without AS recurrent MI rates per 100 person-years were 8.7 in Sweden 
and 8.2 in Denmark. For patients with AS corresponding rates were 29.5 and 23.9, 
respectively. Patients with AS also had a significantly higher risk for recurrent MI in 
both countries in the adjusted model (Sweden, HR: 2.13, 95% CI=1.85-2.44, 
Denmark HR: 1.48, 95% CI=1.28-1.71). Combining results from both countries 
resulted in an HR of 1.78 (95% CI=1.25-2.54). In both countries, patients who 
underwent percutaneous revascularization had similar findings (HR: 2.19, 95% CI 
1.58-3.03 and 1.62, 95% CI=1.24-2.12 for patients with DAPT and AS). 
 
Mortality rates 
Mortality analyses indicated a substantially higher mortality for patients with aortic 
stenosis compared to patients without aortic stenosis. All-cause mortality rates are 
shown in Table 2. Patients with bleeding events had higher subsequent mortality rates 
than those without bleeding events; the mortality rates were 49.1 (95% CI 43.3-55.7) 
and 21.7 (95% CI 19.4-24.3) vs 7.7 (95% CI 7.4-7.9) and 6.1 (95% CI 5.9-6.3) per 
100 person-years in Sweden and Denmark respectively. Mortality rates after a 
bleeding event were 73.5 (95% CI 51.7-104.6) in Sweden and 34.2 (95% CI 25.7-
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45.6) in Denmark for those with aortic stenosis vs 46.8 (95% CI 40.9-53.9) and 20.4 
(95% 18.0-23.0) per 100 person-years in patients without aortic stenosis. 
 
In the adjusted analyses patients with AS had approximately 2-fold increased risk of 
mortality in Sweden (HR: 2.09, 95% CI=1.85-2.35) and a 1.5-fold increased mortality 
risk in Denmark (HR: 1.48, 95% CI=1.32-1.67) compared to patients without AS. 
Combined results from both countries rendered an HR of 1.76 (95% CI=1.26-2.47). 
The risk for all-cause mortality for patients with AS was increased in the subgroup 
who underwent PCI in both Sweden (HR: 2.35, 95% CI 1.54-3.59) and Denmark 
(2.17 95% CI=1.71-2.75). 
 
Oral anticoagulant therapy 
Patients receiving oral anticoagulant treatment in addition to DAPT had higher 
bleeding rates; 5.6 and 8.4 in Sweden and Denmark, respectively. Recurrent MI and 
all-cause mortality were also more common, with incidence rates of 10.1 and 12.8 for 
recurrent MI and 7.8 and 11.2 for all-cause mortality in Sweden and Denmark. After 
combining the results from both countries patients without AS on DAPT and 
receiving warfarin therapy had an increased risk for bleeding (HR 1.48, 95% CI=1.27-
1.73). Patients with AS receiving both DAPT and oral anticoagulant therapy had an 
increased risk for bleeding (HR 2.47, 95% CI=1.56-3.90), recurrent MI (HR 1.73, 
85% CI=1.22-2.45) and all-cause mortality (HR 1.34 95% CI=1.00-1.80), compared 
with individuals without AS not receiving oral anticoagulant therapy. 
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Sensitivity analysis 
Due to potential changes in PCI techniques and safety and efficacy of antiplatelet 
therapy, we also tested for interactions between calendar year and PCI in the cohorts. 
P-values for interactions were 0.36 (Sweden) and 0.84 (Denmark) for bleeding, 0.52 
(Sweden) and 0.25 (Denmark) for recurrent myocardial infarction, and 0.95 (Sweden) 
and 0.18 (Denmark) for all-cause mortality, respectively. 
 
Sources of bleeding 
Gastrointestinal bleeding was most common bleeding site for both patients with AS 
(34.5%) and without AS (31.0%). Hematuria (18.9% and 22.0% respectively) and 
epistaxis (12.1% and 13.5%) were also common sites of bleeding in these patients. 
Cerebral bleeding events were rare in both patient groups (3.9% for AS patients and 
4.3%). Iron-deficiency anemia due to chronic blood loss without a specified site of 
bleeding was common (20.9% for AS patients and 16.1% for non-AS patients).     
 
 
 
  
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
 
 15 
Discussion 
 
In the current study, including nationwide data from two countries, we observed that 
AS was associated with an increased risk of bleeding after MI in Sweden but not in 
Denmark, but also a significantly increased risk for both recurrent MI and all-cause 
mortality in both countries. The differences remained after adjustments for age, sex 
and common comorbidities and were robust when pooling data from both countries. 
Patients with AS were older and had a higher burden of comorbid conditions such as 
diabetes, heart failure and previous ischemic heart disease. It is possible that they 
represent a group with more advanced cardiovascular and atherosclerotic disease, 
which in part could explain some of the findings in the current study. However, the 
observations remained after adjustment for both age and comorbidity, suggestive that 
factors related to AS itself might confer an increased risk. AS has previously been 
shown to be associated with an increased bleeding risk due to loss of large vWF 
multimers with impaired hemostasis as a result (16). Impaired hemostasis mainly 
occur in subjects with severe AS and less frequently in cases with mild to moderate 
disease. Previous validation of AS cases in the Swedish registers have found that a 
diagnosis of AS mainly represent moderate to severe disease implicating acquired von 
Willebrand disease as one of the potential mechanisms behind the results observed in 
this study. It is possible that the lower risk estimates in the Danish population might 
reflect different diagnostic traditions with relatively milder disease being diagnosed in 
Denmark. Interestingly, the proportion of bleeding events due to gastrointestinal or 
iron-deficiency anemia (most likely due to gastrointestinal bleeding) were higher in 
patients with AS, in line with current understanding of the pathophysiology behind 
AS related bleeding. 
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In patients with AS, it is possible that reducing the time of DAPT could prove 
beneficial. To our knowledge, this is the first report on the worse clinical outcomes 
associated with AS in an era of modern aggressive antiplatelet therapy.  
 
Increased risk for recurrent MI 
Although we observed that the bleeding risk was increased for patients with AS, these 
patients were also at a higher risk for recurrent MI, consistent with previous studies 
which have reported a procoagulative state for some patients with AS (20).  
Our findings thus highlight the complexity of antiplatelet therapy in this high-risk 
population, and suggest that individualized decisions on selection of antiplatelet 
inhibitors guided by vWF analysis may be warranted. However, additional studies are 
needed to characterize the prevalence of vWF abnormalities in AS patients with 
moderate and severe AS, and comparisons of different antiplatelet therapies in this 
context. 
AS results in obstruction of the outflow tract of the left ventricle, increasing strain on 
the left ventricle. In combination with comorbid conditions such as anemia, infection 
or trauma, this increasing strain may result in insufficient oxygen delivery to 
myocardial cells resulting in a strain-induced form of MI not necessarily due to 
coronary obstruction, referred to as MI type 2. AS patients are at increased risk for MI 
type 2 compared to patients without AS, which could contribute to the higher risk for 
recurrent MI and lower use of revascularization observed in this study. 
Revascularization therapy within 30 days for AS patients was only utilized in 28% 
and 40% in Sweden and Denmark, respectively. Although the restriction of our study 
population to patients with DAPT is likely to results in exclusion of a number of 
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patients with MI type 2, to whom DAPT is not uniformly prescribed, our findings of 
high bleeding rates further highlight the risks of DAPT in this context. As already 
shown in previous studies, bleeding events were associated with higher subsequent 
mortality rates (30). There were no significant discrepancies in findings between the 
group who had revascularization performed and the main analysis, supporting the 
validity of the findings. 
 
Similar findings were observed in both countries, however, small differences between 
the countries were noted, and previous ischemic heart disease was strikingly more 
common in Denmark than in Sweden. This might reflect different risk factor exposure 
in the two countries and when comparing the actual rates between the countries 
caution is advised. 
 
Added treatment of oral anticoagulants enhanced the bleeding risk for patients with 
AS quite substantially. A small but statistically significant increase in bleeding risk 
was noticed in the population without AS. The added bleeding risk associated with 
oral anticoagulant therapy was more pronounced for patients with AS compared to 
patients without AS when combining data from both countries. The results from the 
combined model suggests that the loss of vWF multimers have an additive effect 
when antiplatelet therapy is combined with anticoagulant therapy, as would be 
expected. However, there were few AS patients receiving both oral anticoagulants and 
DAPT.  
 
Study limitations 
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This study was based on nationwide registries and as such has some inherent 
limitations. For example, echocardiographic data was unavailable which leads to 
uncertainty in diagnostic accuracy. The diagnosis of both AS and MI were based upon 
a registry diagnosis requiring hospitalization which could potentially lead to missed 
cases. Nevertheless, acute myocardial infarction is typically a medical emergency and 
these patients are highly unlikely to be treated for in a non-hospital setting. After MI, 
patients undergo rigorous examinations, normally including both echocardiography 
and coronary angiography. In both Sweden and Denmark these patients are generally 
treated in a cardiology ward. Clinically significant AS is likely to be diagnosed upon 
routine echocardiographic examination post-MI, resulting in a limited proportion of 
undiagnosed AS but also an increased probability of clinically insignificant cases of 
AS. Bleeding is traditionally considered difficult to evaluate in register studies. The 
few validation studies which have evaluated bleeding events however have shown a 
high positive predictive value in Scandinavian registers and that bleeding events are 
unlikely to be miss-diagnosed (31).
 
As with all observational studies, residual 
confounding cannot be ruled out. The meta-analysis comparing data from registries 
gathered in two different countries and during different time periods could possibly 
contain some heterogeneity in the population and therefore the effect estimates and 
should be interpreted with some caution. Despite these limitations, there were also 
several strengths in our nationwide data from two countries. For example, the 
coverage in these registries is exceptional and the validity of the cardiovascular 
diagnoses has proven to be high (23,27-28).  
 
Conclusions 
AS is associated with a substantially increased occurrence of recurrent MI and all-
cause mortality after MI. Bleeding events were numerically more common in patients 
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with AS and a statistically significant increased risk was found in the adjusted 
analysis in Sweden, but not in Denmark. Careful evaluation and monitoring of these 
patients are recommended and the risk-benefit of DAPT might be different for these 
patients after MI. Prospective studies of vWF abnormalities and randomized studies 
of antiplatelet regiments are needed to determine optimal therapy in patients with AS. 
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Figure legends 
Figure 1. Forest plot illustrating the results from meta-analysis, combining results 
from both countries. AS = Aortic stenosis. DAPT = Dual antiplatelet therapy.  
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Table 1. Patient characteristics in Denmark and Sweden separated into patients with 
or without concurrent AS. 
 
Denmark Sweden 
 
No Aortic 
Stenosis 
Aortic 
stenosis 
No Aortic 
Stenosis 
Aortic 
stenosis 
N 48782 (97%) 1525 (3%) 49173 (97%) 1287 (3%) 
Age  66 (13) 79 (10) 70 (12) 76 (11) 
Male sex  68% 51% 64% 56% 
Diabetes  11% 17% 15% 20% 
Previous IHD 46% 54% 26% 39% 
Congestive heart failure 14% 31% 16% 23% 
Kidney disease 2% 6% 3% 4% 
Prior bleeding  3% 8% 4% 6% 
Atrial fibrillation 8% 22% 12% 16% 
COPD 6% 12% 4% 5% 
Cerebrovascular disease 5% 12% 7% 9% 
     Treatment 
    
     PCI within 30 days post-MI 71% 38% 58% 26% 
CABG within 30 days post-
MI 4% 2% 2% 2% 
     Use of oral anticoagulants 5% 10% 3% 5% 
Use of statins  90% 73% 85% 75% 
Use of beta blockers  84% 78% 90% 88% 
Use of RAAS-inhibitors  50% 50% 74% 68% 
Use of insulin 4% 6% 8% 12% 
Use of loop diuretics  20% 54% 27% 49% 
Table 1. Patient characteristics. N = Number of subjects. IHD = Ischemic heart disease. COPD = 
Chronic obstructive pulmonary disease. PCI = Percutaneous coronary intervention. CABG = Coronary 
artery bypass grafting. RAAS = Renin-angiotensin-aldosterone system. 
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Table 2. Association with all-cause mortality, recurrent MI and bleeding after 
myocardial infarction in patients with DAPT comparing patients with and without 
aortic stenosis. 
 All-cause mortality Recurrent MI Bleeding 
Events / person-years 
(PY) Sweden Denmark Sweden Denmark Sweden Denmark 
DAPT, no AS 
2,885 / 
40,868 
2,495 / 
42,755 
3,314 / 
38,246 
3,267 / 
40,211 
1,254 / 
39,183 
1,367 / 
41,305 
DAPT with oral 
anticoagulants, no AS 106 / 1,366 
234 / 
2,086 
123 / 
1,214 
203 / 
1,584 
69 / 
1,236 
135 / 
1,613 
DAPT and AS 
263 / 916 
344 / 
1,121 226 / 767 
215 / 
898 75 / 817 77 / 928 
DAPT with oral 
anticoagulants, AS 8 / 44 36 / 112 8 / 41 26 / 79 3 / 43 17 / 76 
Incidence rate (events / 
100 PY) 
      
DAPT, no AS 
7.1 (6.8-
7.3) 
5.8 (5.6-
6.1) 
8.7 (8.4-
9.0) 
8.2 (7.9-
8.4) 
3.2 (3.0-
3.4) 
3.3 (3.1-
3.5) 
DAPT with oral 
anticoagulants, no AS 
7.8 (6.4-
9.4) 
11.2 (9.9-
12.8) 
10.1 (8.5-
12.1) 
12.8 
(11.2-
14.7) 
5.6 (4.4-
7.1) 
8.4 (7.1-
9.9) 
DAPT and AS 28.7 
(25.4-32.4) 
30.7 
(27.6-
34.1) 
29.5 
(25.9-
33.6) 
23.9 
(20.9-
27.4) 
9.2 (7.3-
11.5) 
8.3 (6.6-
10.4) 
DAPT with oral 
anticoagulants, AS 
18.0 (9.0-
36.1) 
32.2 
(23.2-
44.6) 
19.6 (9.8-
39.3) 
32.8 
(22.3-
48.1) 
7.1 (2.3-
21.9) 
22.3 
(13.9-
35.9) 
Table 2. DAPT: Dual-antiplatelet therapy, AS: Aortic valvular stenosis, MI: Myocardial infarction, 
PY: Person-years.  
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Table 3. Adjusted hazard ratios for all-cause mortality, recurrent MI and bleeding 
after myocardial infarction in patients with DAPT comparing patients with and 
without aortic stenosis. 
 
 
All-cause mortality Recurrent MI Bleeding 
 
Sweden Denmark Sweden Denmark Sweden Denmark 
DAPT, no AS 
1.00 
(reference) 
1.00 
(reference) 
1.00 
(reference) 
1.00 
(reference) 
1.00 
(reference) 
1.00 
(reference) 
DAPT with oral 
anticoagulants, no 
AS 
0.97  
(0.80-1.18) 
1.07  
(0.92-1.24) 
1.09  
(0.91-1.31) 
1.10  
(0.94-1.28) 
1.43  
(1.11-1.84) 
1.51  
(1.23-1.85) 
DAPT and AS 
2.09  
(1.85-2.35) 
1.48  
(1.32-1.67) 
2.13  
(1.85-2.44) 
1.48  
(1.28-1.71) 
2.04  
(1.61-2.59) 
1.24  
(0.98-1.57) 
DAPT with oral 
anticoagulants, AS 
1.67  
(0.90-3.12) 
1.26  
(0.90-1.77) 
1.75  
(0.87-3.50) 
1.73  
(1.16-2.57) 
1.73  
(0.56-5.38) 
2.65  
(1.61-4.36) 
Table 3. DAPT: Dual-antiplatelet therapy, AS: Aortic valvular stenosis, MI: Myocardial infarction, 
Adjusted for age, sex, percutaneous interventions and CABG performed within 30 days after index 
event, treatment with NSAIDs, proton pump inhibitors, beta blockers, statins, calcium blockers, 
thiazides, loop diuretics, spironolactone, and/or insulin, previous diagnosis of ischemic heart disease, 
cerebrovascular disease, peripheral arterial disease, liver disease, chronic kidney disease, peptic ulcer 
disease, chronic obstructive pulmonary disease, rheumatic disease, atrial fibrillation, cancer, bleeding, 
and congestive heart failure. 
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Outcomes associated with dual antiplatelet therapy 
after myocardial infarction in patients with aortic 
stenosis 
 
Highlights 
 
Bleeding was more common in AS patients treated with DAPT after MI  
 
Recurrent MI and all-cause mortality were more frequent in AS patients 
 
Patients with AS represents a group with high risk after incident MI  
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